Search results
Results from the WOW.Com Content Network
IL13RA2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: Q14627 (Interleukin-13 receptor subunit alpha-2) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public ...
IL-13 uses the IL-4 receptor type II (IL-4RII), a complex formed by an IL-4Rα chain and an IL-13Rα1 chain. Initially, the ligand (IL-4 or IL-13) binds to the IL-4Rα chain and IL-13Rα1 respectively; thereafter, a secondary chain (IL-13Rα1 and IL-4Rα respectively) will also bind, forming the complete IL-4RII.
A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. [1] The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.
Act1 is an important protein for the immune system functions. [1] Furthermore, its dysfunction is involved in autoimmunity or other diseases, such as allergic airway inflammation [1] or psoriatic arthritis. [4] When the Th17 cell number is enhanced, it leads to the over-production of IL-17, inducing Act1 activation and inflammation, and ...
These delivery mechanisms serve to address the limitations of CAR-T cells in translational experimentation and clinical trials, including shelf-life, off-target effects, and tumor infiltration. [1] As of April 2023, six CAR-T cell therapies are clinically approved by the FDA , all of which target hematologic (blood-based) cancers, including ...
Type II cytokine receptors, also commonly known as class II cytokine receptors, are transmembrane proteins that are expressed on the surface of certain cells. They bind and respond to a select group of cytokines including interferon type I, interferon type II, interferon type III.
The CAR programs the T cells to target an antigen present on the tumor cell surface. For safety, CAR T cells are engineered to be specific to an antigen that is expressed on a tumor cell but not on healthy cells. [2] After the modified T cells are infused into a patient, they act as a "living drug" against cancer cells. [3]
The protein encoded by this gene is a decoy receptor for certain cytokines that belongs to the interleukin-1 receptor family. This protein binds interleukin-1α (IL1A), interleukin-1β (IL1B), and interleukin 1 receptor antagonist (IL1Ra), preventing them from binding to their regular receptors and thereby inhibiting the transduction of their signaling.